Clinical trials
Gastro-esophageal Junction Cancer clinical trials
Below are recruiting gastro-esophageal junction cancer clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT06496789RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
TianjinAges 18–75 - NCT06962137RecruitingPhase 2
Zolbetuximab plus two chemos for CLDN18.2-positive stomach cancer
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
AntwerpAges 18 years+ - NCT04592211RecruitingPhase 1/Phase 2
Study pembrolizumab plus olaparib for stomach cancer after treatment
This Phase 1/2 study tests whether combining pembrolizumab (an immunotherapy) with olaparib (a targeted cancer pill) can shrink or control recurrent or advanced stomach and GEJ cancer. You may be eligible if your cancer has already been treated with trastuzumab and certain body-function and blood/vital checks look safe.
SeoulAges 19 years+ - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Jacksonville, FloridaAges 18 years+ - NCT01048281Recruiting
Study of stomach and esophagus cancer samples
This study looks at stomach (gastric) and esophagus cancer, using clinical information and tissue samples. It may help researchers better understand these cancers and improve future care.
Stanford, CaliforniaAges 18 years+ - NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT05055648RecruitingPhase 3
Proton vs photon radiation for esophageal cancer before surgery
This trial compares proton therapy and standard photon therapy given before surgery for esophageal (or stomach–esophagus) cancer. It aims to see which radiation approach works better and is safer as part of a combined treatment plan.
LeuvenAges 18 years+ - NCT04652180Recruiting
Robot surgery versus open surgery for esophagus cancer
This trial compares robot-assisted surgery with the standard open chest operation to remove esophagus and nearby tissue. It may help you understand which approach works better and is safer for patients whose cancer can be surgically removed.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT04306458Recruiting
Testing robot-assisted vs standard surgery for resectable esophageal cancer
This trial compares a robot-assisted approach to a standard minimally invasive approach for surgery in people with certain types of esophageal or gastroesophageal junction cancer that can be removed. It aims to see which surgery method works better and is safer for these patients.
MainzAges 18–90 - NCT05865743RecruitingPhase 3
Antibiotic cloth before surgery to prevent esophagus infection
This Phase 3 trial tests whether using an antibiotic decolonization treatment around the time of esophagus surgery can reduce serious infections afterward. It may help you lower the risk of postoperative infectious complications after curative esophagectomy or esophagus reconstruction.
LeuvenAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT05944237RecruitingPhase 1/Phase 2
Early trial for advanced cancers using HTL0039732
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
CambridgeAges 18 years+
Hear when a new Gastro-esophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastro-esophageal junction cancer?
- Yes. Clin2 currently lists 15 recruiting gastro-esophageal junction cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastro-esophageal junction cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastro-esophageal junction cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.